Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

Capping patient out-of-pocket costs for insulin has been a popular move for legislators, most recently by the US House. On this episode we weigh the Pros, Cons, and viral reactions to this move including lowering vs. shifting costs, ADA guidelines, and political theater.

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

After explaining a HORRENDOUS mistake made recently by the NABP and the oversight of NAPLEX testing that affected one of our own, we decided it's high time we dove into the controversy around the use of ivermectin against COVID-19. Social media and mainstream news can be confusing, so we tried to summarize while sticking to what is known. If we missed something, please let us know!

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

On this episode we were blessed to have on Kyle McCormick, owner/operator of Blueberry Pharmacy, to explain his unique (but traditionally familiar) business model. Blueberry operates on a cost-plus model and DOES NOT ACCEPT INSURANCE. Crazy? Maybe not. Kyle explains why he thinks we need different payment systems for cheap generics than expensive brand names, circumventing PBMs when they aren't necessary.

https://blueberrypharmacy.com/

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

The Twittersphere recently noticed that quoted savings on Amazon Pharmacy are a little bit unrealistic. On this episode we break down how a pharmacy's "Usual & Customary" price SHOULD be calculated, what it is used for, and what Amazon's crazy numbers say about their pharmacy business model.

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

The COVID-19 pandemic highlighted many weaknesses in the US Drug Supply Chain's dependence on foreign production (similar to toilet paper, masks, etc.). The Biden White House recently announced plans to address supply chain weaknesses to prevent future shortages due to overseas dependence.

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

After a brief hiatus we are back in the studio! Everyone has important life updates to share, Aaron has some interesting learning points about Medicaid rebates, Ryan explains DIR fees, and we check back in with GoodRx's recent stock price woes.

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

Since we have had guests on for the last few episodes, we wanted to take some time to cover some recent topics that have come up in the first quarter of 2021. Chosen topics:

Aaron - COVID vaccine hesitancy

Ryan - Inclusion of indications on prescriptions

Josh - Stimulus and the child tax credit

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/